press center press release

Gemphire Therapeutics Inc. (Nasdaq: GEMP) to Ring The Nasdaq Stock Market Closing Bell

Published

ADVISORY, Aug. 07, 2017 (GLOBE NEWSWIRE) --

What:

Gemphire Therapeutics Inc. (Nasdaq:GEMP), a clinical-stage biopharmaceutical company that is developing and commercializing therapies to help patients with cardiometabolic disorders, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Dr. Charles Bisgaier,Chairman & CSO / Co-Founder, will ring the Closing Bell.

Where:

Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Tuesday, August 8, 2017 – 3:45 p.m. to 4:00 p.m. ET

Gemphire Therapeutics Inc. Contact:

Jeff Mathiesen

(734) 245-1700

jmathiesen@gemphire.com

Nasdaq MarketSite:

Emily Pan

(646) 441-5120

emily.pan@nasdaq.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West

18 mhz Lower

DL 3811 Vertical

FEC 3/4

SR 13.235

DR 18.295411

MOD 4:2:0

DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:

http://www.facebook.com/NASDAQ.

For photos from ceremonies and events, please visit our Instagram page:

http://instagram.com/nasdaq

For livestream of ceremonies and events, please visit our YouTube page:

http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page:

http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page:

http://nasdaq.tumblr.com/

Webcast:

A live stream of the Nasdaq Closing Bell will be available at:

https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your choice.

About Gemphire Therapeutics Inc.

Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. The Company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care especially statins that will benefit patients, physicians, and payors. Gemphire has initiated 3 clinical trials for homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH)/atherosclerotic cardiovascular disease (ASCVD), and severe hypertriglyceridemia (SHTG) under NCT02722408, NCT02634151, and NCT02944383, respectively with a fourth planned trial in NASH to initiate in second half of 2017. Please visit www.gemphire.com for more information.

About Nasdaq:

Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com

-NDAQA-

In This Story

NDAQ

Nasdaq Press Center

Read the latest press releases, request a press kit, and get in touch with our press team.

learn more